Benefits
The form used in the published urolithin A trials
Most of the published human trials of direct urolithin A have used Mitopure®, so the clinical record on this compound is largely a record of this particular material. That is a sourcing fact rather than a benefit, and it says nothing about how well the ingredient works. Whether the price is worth paying is a judgment for the buyer to make against the trial results below.
Foundational mitochondrial function trials
Trials using Mitopure® report changes in mitochondrial gene expression and in blood markers such as acylcarnitines in middle-aged adults (PMID 35584623). These are laboratory markers, not outcomes a user can feel, and better markers have not yet translated into a met primary endpoint in either performance trial.
Muscle strength preservation
The ATLAS trial (Cell Reports Medicine, 2022; PMID 35584623) reported that Mitopure® at 500-1,000 mg/day improved muscle strength by about 12% over 4 months in middle-aged adults. Important transparency note: the trial failed its primary endpoint, peak power output. The strength result is a secondary endpoint, as are the aerobic endurance (VO2 peak) and 6-minute walk results. A second trial, in 42 trained male distance runners in 2025, also missed its primary endpoint (PMID 40839339). Two trials and two missed primaries mean the strength signal should be read as promising secondary-endpoint evidence rather than a settled effect.
New Dietary Ingredient notification on file with FDA
Amazentis submitted a New Dietary Ingredient (NDI) notification for Mitopure® and FDA did not object to it. That means the agency raised no concerns about the safety information submitted for the stated conditions of use. It is not FDA approval, and it is not validation of any claim: FDA does not approve dietary supplements and does not review whether an ingredient works. The filing is a real regulatory step, and more than many branded ingredients have, but it should not be read as a government endorsement.
Mitophagy mechanism with documented effects
Urolithin A induces mitophagy, the clearing of damaged mitochondria, and participants taking Mitopure® show related changes in gene and mitophagy protein expression (PMID 35584623). That is a mechanism with biomarker support, not a measured health outcome, so it is the reason the ingredient is worth testing rather than proof that it delivers a benefit.
Independent of gut microbiome conversion
Mitopure® provides direct urolithin A regardless of individual gut microbiome conversion capacity. This is a genuine advantage over dietary ellagitannin sources such as pomegranate and walnuts, since a majority of people, commonly estimated at around 60 to 70 percent, do not efficiently convert them to urolithin A. Estimates vary between populations and this figure should be treated as approximate.
Most of the evidence is industry funded
Amazentis, the company that sells the ingredient, funds or co-authors most of the published urolithin A research and has further trials underway. Ongoing trials have no results and support no claim. The industry involvement does not make the existing findings wrong, but it is worth knowing when weighing them.
Mechanism of action
Mitophagy induction
Mitopure® urolithin A induces mitophagy — the cellular cleanup process that removes damaged mitochondria and supports renewal. Mechanism foundation for the cellular aging and muscle preservation applications.
Mitochondrial biogenesis support
Beyond clearing damaged mitochondria, urolithin A has been reported to support mitochondrial biogenesis, mostly in cell and animal work. This is a proposed mechanism rather than a measured outcome in people.
Direct supplementation bypasses gut conversion
Mitopure® direct urolithin A delivery bypasses individual variation in gut microbial conversion of dietary ellagitannins. Provides reproducible urolithin A levels across users regardless of microbiome status.
Clinical trials
The ATLAS trial (Cell Reports Medicine, 2022) in 88 middle-aged adults at 500-1,000 mg/day for 4 months documented mitochondrial gene expression improvements, mitochondrial biomarker enhancement, and ~12% muscle strength improvement.
Clinical population described in trial publication.
The ATLAS trial (Cell Reports Medicine, 2022; PMID 35584623) in 88 middle-aged adults at 500-1,000 mg/day for 4 months reported changes in mitochondrial gene expression, in mitochondrial biomarkers, and about 12% greater muscle strength. It failed its primary endpoint: the authors state plainly that they did not see a significant improvement in peak power output. Everything positive here is a secondary endpoint, which is a weaker form of evidence, and saying so clearly matters more than the headline number.
Trials in older adults show Mitopure® preserves muscle strength and endurance over 4+ months of supplementation.
older adults
The 4-month trial in middle-aged adults found about 12% greater muscle strength (PMID 35584623), and the 4-week trial in 42 trained male distance runners found lower muscle damage markers (p<0.0001) and lower perceived exertion (p=0.02) (PMID 40839339). Both are secondary endpoints in trials that missed their primary endpoints, and neither trial was run in older adults or in people with age-related muscle loss.
Amazentis runs ongoing clinical trials across aging, athletic performance, and skin health.
Clinical population described in trial publication.
This entry is not a clinical trial and reports no results. Amazentis has further trials underway in several areas, but unpublished and ongoing work cannot support any claim about what the ingredient does.